Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Development And Validation Of The Ace Tool: Assessing Medical Trainees' Competency In Evidence Based Medicine, Dragan Ilic, Rusli Bin Nordin, Paul Glasziou, Julie Tilson, Elmer Villanueva
Development And Validation Of The Ace Tool: Assessing Medical Trainees' Competency In Evidence Based Medicine, Dragan Ilic, Rusli Bin Nordin, Paul Glasziou, Julie Tilson, Elmer Villanueva
Paul Glasziou
Background: While a variety of instruments have been developed to assess knowledge and skills in evidence based medicine (EBM), few assess all aspects of EBM - including knowledge, skills attitudes and behaviour - or have been psychometrically evaluated. The aim of this study was to develop and validate an instrument that evaluates medical trainees' competency in EBM across knowledge, skills and attitude. Methods. The 'Assessing Competency in EBM' (ACE) tool was developed by the authors, with content and face validity assessed by expert opinion. A cross-sectional sample of 342 medical trainees representing 'novice', 'intermediate' and 'advanced' EBM trainees were recruited …
Which Lipid Measurement Should We Monitor? An Analysis Of The Lipid Study, Paul Glasziou, Les Irwig, Adrienne Kirby, Andrew Tonkin, R J. Simes
Which Lipid Measurement Should We Monitor? An Analysis Of The Lipid Study, Paul Glasziou, Les Irwig, Adrienne Kirby, Andrew Tonkin, R J. Simes
Paul Glasziou
Objectives: To evaluate the optimal lipid to measure in monitoring patients, we assessed three factors that influence the choice of monitoring tests: (1) clinical validity; (2) responsiveness to therapy changes and (3) the size of the long-term ‘signal-to-noise’ ratio. Design: Longitudinal analyses of repeated lipid measurement over 5 years. Setting: Subsidiary analysis of a Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study—a clinical trial in Australia, New Zealand and Finland. Participants: 9014 patients aged 31–75 years with previous acute coronary syndromes. Interventions: Patients were randomly assigned to 40 mg daily pravastatin or placebo. Primary and secondary outcome measures: We …